MASH

Semaglutide for MASH: Novo Nordisk Data Reveals Breakthrough at EASL 2026

By Regulatory Intelligence Desk
19 May 2026

Semaglutide for MASH (Metabolic Dysfunction-associated Steatohepatitis) is poised to change the landscape of hepatology as Novo Nordisk prepares to unveil highly anticipated data at the [Read More…]

Regulatory Approval Healthcare & Pharmaceuticals News

Novo Nordisk’s Wegovy® (Semaglutide) Receives FDA Approval for MASH Treatment

By Ajmal Aseem
18 August 2025

Novo Nordisk’s Wegovy has received FDA approval to treat MASH, a serious liver disease linked to obesity and diabetes. This new indication highlights Wegovy’s role in improving liver fibrosis and reversing liver damage alongside lifestyle changes.

Tag: MASH

Semaglutide for MASH: Novo Nordisk Data Reveals Breakthrough at EASL 2026

Novo Nordisk’s Wegovy® (Semaglutide) Receives FDA Approval for MASH Treatment

Areas Covered

Discover More

Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN

LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C

GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline

Johnson & Johnson Q2 2026 Analysis: Company Reports $25.3 Billion in Sales, Raises Full-Year Outlook

Merck’s Erbitux BRAF V600E mCRC Regimen Gets EU Approval for First-Line Treatment

AstraZeneca Zegfrovy Deal: AstraZeneca Licenses Dizal’s Oral EGFR Inhibitor for Lung Cancer in Up to $1.5 Billion Agreement